Published in J Clin Oncol on November 01, 2005
Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res (2009) 2.13
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol (2009) 1.82
Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol (2009) 1.33
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clin Cancer Res (2009) 1.30
Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer (2011) 1.28
Fractal dimension of chromatin is an independent prognostic factor for survival in melanoma. BMC Cancer (2010) 1.14
Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer (2009) 1.03
Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes Cancer (2010) 1.00
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma. J Invest Dermatol (2010) 0.95
Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation. Oncotarget (2014) 0.92
The influence of dermatologist and primary care physician visits on melanoma outcomes among Medicare beneficiaries. J Am Board Fam Med (2013) 0.89
Pump-probe imaging of pigmented cutaneous melanoma primary lesions gives insight into metastatic potential. Biomed Opt Express (2015) 0.86
A nine-gene signature predicting clinical outcome in cutaneous melanoma. J Cancer Res Clin Oncol (2012) 0.84
Stage-specific prognostic biomarkers in melanoma. Oncotarget (2015) 0.83
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. Br J Cancer (2011) 0.80
An attempt at a molecular prediction of metastasis in patients with primary cutaneous melanoma. PLoS One (2012) 0.79
Investigating the utility of human melanoma cell lines as tumour models. Oncotarget (2017) 0.75
Prognostic discrimination of subgrouping node-positive endometrioid uterine cancer: location vs nodal extent. Br J Cancer (2011) 0.75
Prognostic value of sentinel lymph node biopsy in 121 low-risk melanomas (tumour thickness <1.00 mm) on the basis of a long-term follow-up. Eur J Nucl Med Mol Imaging (2011) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
SIVcpz in wild chimpanzees. Science (2002) 2.45
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol (2007) 2.06
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78
Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol (2002) 1.74
Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol (2007) 1.55
Clinical significance of occult metastatic melanoma in sentinel lymph nodes and other high-risk factors based on long-term follow-up. World J Surg (2005) 1.47
Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer (2003) 1.38
Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol (2007) 1.37
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34
Comparison of predictive values of two diagnostic tests from the same sample of subjects using weighted least squares. Stat Med (2006) 1.28
Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol (2008) 1.19
Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol (2007) 1.16
Differentiation of normal skin and melanoma using high resolution hyperspectral imaging. Cancer Biol Ther (2006) 1.16
Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol (2011) 1.15
Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol (2005) 1.11
Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer (2006) 1.08
A four-parameter logistic model for estimating titers of functional multiplexed pneumococcal opsonophagocytic killing assay. J Biopharm Stat (2008) 1.05
Comparison of multivariate adaptive regression splines and logistic regression in detecting SNP-SNP interactions and their application in prostate cancer. J Hum Genet (2008) 1.02
Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther (2006) 1.00
Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg (2006) 0.97
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol (2011) 0.97
Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol (2011) 0.94
Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol (2006) 0.93
Sunbeds and sunlamps: who used them and their risk for melanoma. Pigment Cell Melanoma Res (2011) 0.92
Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer (2004) 0.92
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol (2014) 0.91
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol (2013) 0.89
Retracted Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort. J Clin Oncol (2005) 0.89
Characteristics associated with early and late melanoma metastases. Cancer (2010) 0.88
Local immune response predicts survival in patients with thick (t4) melanomas. Ann Surg Oncol (2013) 0.86
4-Hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers in mice: characterization of FHIT and survivin expression and chemopreventive effects of indomethacin. Carcinogenesis (2004) 0.86
Desmoplastic neurotropic melanoma of the head and neck: the role of radiation therapy. Head Neck (2002) 0.86
Predicting outcomes in metastatic melanoma. J Clin Oncol (2008) 0.85
Randomized, controlled surgical trial of preoperative tumor curettage of basal cell carcinoma in Mohs micrographic surgery. J Am Acad Dermatol (2004) 0.83
Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck (2003) 0.82
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors. J Clin Pharmacol (2013) 0.82
Sentinel node positive melanoma patients: prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. Ann Surg Oncol (2010) 0.81
Eruptive disseminated Spitz nevi. J Am Acad Dermatol (2007) 0.80
Gene selection for oligonucleotide array: an approach using PM probe level data. Bioinformatics (2004) 0.80
Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother (2003) 0.80
In response to "Drug metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort". J Clin Oncol (2007) 0.79
An integrated tree-based classification approach to prognostic grouping with application to localized melanoma patients. J Biopharm Stat (2007) 0.78
Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat (2009) 0.78
Turning Access into a web-enabled secure information system for clinical trials. Clin Trials (2009) 0.78
Predicting the risk of axillary nodal metastases and their use in selecting breast surgery options. J Clin Oncol (2009) 0.77
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Invest New Drugs (2013) 0.76
A chain reaction approach to modelling gene pathways. Transl Cancer Res (2012) 0.75
Lymphatic invasion as a prognostic biomarker in primary cutaneous melanoma. Methods Mol Biol (2014) 0.75
Effectiveness of multiple internal standards: deuterated analogues of methylenedioxymethamphetamine, methylenedioxyamphetamine, methamphetamine, and amphetamine. J Anal Toxicol (2004) 0.75
A two-stage binomial test approach of gene identification in oligonucleotide arrays. J Biopharm Stat (2007) 0.75
Optimal designs for two-arm, phase II clinical trial design with multiple constraints. J Biopharm Stat (2010) 0.75
The influence of staging laparotomy for cervical cancer on patterns of recurrence and survival. Int J Gynecol Cancer (1993) 0.75